| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Karin Boer, Dirk Troost, Floor Jansen, Mark Nellist, Ans M W van den Ouweland, Jeroen J G Geurts, Wim G M Spliet, Peter Crino, Eleonora Aronic. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology : official journal of the Japanese Society of Neuropathology. vol 28. issue 6. 2009-01-28. PMID:18410267. |
immunocytochemical analysis of the tsc brain lesions confirmed the cell-specific activation of the mtor pathway in cortical tubers, sens and cerebellum, as well as differential cellular localization of hamartin and tuberin, the tsc1 and tsc2 gene products. |
2009-01-28 |
2023-08-12 |
Not clear |
| M Shiono, T Kobayashi, R Takahashi, G Sun, M Abe, D Zhang, L Wang, X Piao, Y Takagi, R Mineki, H Taka, N Tada, S Sonobe, S Momose, M Ueda, O Hin. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. Oncogene. vol 27. issue 52. 2008-11-18. PMID:18695678. |
tuberin, a tumor-suppressor protein produced by the tuberous sclerosis gene tsc2, downregulates the rheb-mtor-s6k pathway (mtor axis). |
2008-11-18 |
2023-08-12 |
human |
| Margit Rosner, Michaela Hanneder, Nicol Siegel, Alessandro Valli, Christiane Fuchs, Markus Hengstschläge. The mTOR pathway and its role in human genetic diseases. Mutation research. vol 659. issue 3. 2008-10-14. PMID:18598780. |
mutations in the mtor pathway component genes tsc1, tsc2, lkb1, pten, vhl, nf1 and pkd1 trigger the development of the syndromes tuberous sclerosis, peutz-jeghers syndrome, cowden syndrome, bannayan-riley-ruvalcaba syndrome, lhermitte-duclos disease, proteus syndrome, von hippel-lindau disease, neurofibromatosis type 1, and polycystic kidney disease, respectively. |
2008-10-14 |
2023-08-12 |
human |
| Carolyn L Buller, Robert D Loberg, Ming-Hui Fan, Qihong Zhu, James L Park, Eileen Vesely, Ken Inoki, Kun-Liang Guan, Frank C Brosiu. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. American journal of physiology. Cell physiology. vol 295. issue 3. 2008-10-09. PMID:18650261. |
since gsk-3 can inhibit mammalian target of rapamycin (mtor) signaling via phosphorylation of the tuberous sclerosis complex subunit 2 (tsc2) tumor suppressor, we investigated whether chronic gsk-3 effects on glucose uptake and glut1 expression depended on tsc2 phosphorylation and tsc inhibition of mtor. |
2008-10-09 |
2023-08-12 |
Not clear |
| Sangyeul Han, Rochelle M Witt, Túlio M Santos, Carolyn Polizzano, Bernardo L Sabatini, Vijaya Rames. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cellular signalling. vol 20. issue 6. 2008-09-29. PMID:18308511. |
the tumor suppressor tuberin, encoded by the tuberous sclerosis complex (tsc) gene tsc2, negatively regulates the mammalian target of rapamycin (mtor) pathway, which plays a key role in the control of cell growth and proliferation. |
2008-09-29 |
2023-08-12 |
rat |
| Karen H Lu, Weiguo Wu, Bhuvanesh Dave, Brian M Slomovitz, Thomas W Burke, Mark F Munsell, Russell R Broaddus, Cheryl Lyn Walke. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 14. issue 9. 2008-09-18. PMID:18451215. |
although tuberous sclerosis complex 2 (tsc2) is the "gatekeeper" for mtor activation, little is known about defects in the tsc2 tumor suppressor or signaling pathways that regulate tsc2, such as lkb1/amp-activated protein kinase, in the development of endometrial carcinoma. |
2008-09-18 |
2023-08-12 |
Not clear |
| Han C Dan, Albert S Baldwi. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. Journal of immunology (Baltimore, Md. : 1950). vol 180. issue 11. 2008-07-18. PMID:18490760. |
mtor is negatively controlled by the tuberous sclerosis complex 1/2 (tsc1/2), and activation of akt induces phosphorylation of tsc2, which blocks the repressive tsc1/2 activity. |
2008-07-18 |
2023-08-12 |
Not clear |
| Han C Dan, Albert S Baldwi. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. Journal of immunology (Baltimore, Md. : 1950). vol 180. issue 11. 2008-07-18. PMID:18490760. |
insulin activation of mtor requires akt in a manner that involves ikkalpha, preferentially to ikkbeta, and tsc2 phosphorylation. |
2008-07-18 |
2023-08-12 |
Not clear |
| Yutaka Shigeyama, Toshiyuki Kobayashi, Yoshiaki Kido, Naoko Hashimoto, Shun-Ichiro Asahara, Tomokazu Matsuda, Akihiko Takeda, Tae Inoue, Yuki Shibutani, Maki Koyanagi, Tohru Uchida, Maki Inoue, Okio Hino, Masato Kasuga, Tetsuo Nod. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Molecular and cellular biology. vol 28. issue 9. 2008-06-19. PMID:18316403. |
given the role of tuberous sclerosis complex 2 (tsc2) as an upstream molecule of mtor (mammalian target of rapamycin), we examined the effect of tsc2 deficiency on beta-cell function. |
2008-06-19 |
2023-08-12 |
mouse |
| Umut Ozcan, Lale Ozcan, Erkan Yilmaz, Katrin Düvel, Mustafa Sahin, Brendan D Manning, Gökhan S Hotamisligi. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Molecular cell. vol 29. issue 5. 2008-04-28. PMID:18342602. |
loss of the tuberous sclerosis complex genes (tsc1 or tsc2) leads to constitutive activation of mtor and downstream signaling elements, resulting in the development of tumors, neurological disorders, and at the cellular level, severe insulin/igf-1 resistance. |
2008-04-28 |
2023-08-12 |
mouse |
| Shaowei Li, Fumiko Takeuchi, Ji-An Wang, Qingyuan Fan, Toshi Komurasaki, Eric M Billings, Gustavo Pacheco-Rodriguez, Joel Moss, Thomas N Darlin. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 9. 2008-04-18. PMID:18292222. |
patients with tuberous sclerosis complex (tsc) develop hamartomas containing biallelic inactivating mutations in either tsc1 or tsc2, resulting in mammalian target of rapamycin (mtor) activation. |
2008-04-18 |
2023-08-12 |
Not clear |
| Elena A Goncharova, Dmitry A Goncharov, Amelia Chisolm, Matthew S Spaits, Poay N Lim, Gregory Cesarone, Irene Khavin, Omar Tliba, Yassine Amrani, Reynold A Panettieri, Vera P Krymskay. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Molecular pharmacology. vol 73. issue 3. 2008-04-07. PMID:18094073. |
mutational inactivation of tumor suppressor tuberous sclerosis complex 2 (tsc2) in lam constitutively activates the mammalian target of rapamycin (mtor)/p70 s6 kinase 1 (s6k1) signaling pathway and promotes neoplastic growth of lam cells. |
2008-04-07 |
2023-08-12 |
human |
| Jessica K Altman, Patrick Yoon, Efstratios Katsoulidis, Barbara Kroczynska, Antonella Sassano, Amanda J Redig, Heather Glaser, Alison Jordan, Martin S Tallman, Nissim Hay, Leonidas C Platania. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. The Journal of biological chemistry. vol 283. issue 4. 2008-03-26. PMID:18048359. |
on the other hand, as(2)o(3)-dependent induction of apoptosis is diminished in cells with targeted disruption of tsc2, a negative upstream effector of mtor. |
2008-03-26 |
2023-08-12 |
Not clear |
| Z-X Xu, J Liang, V Haridas, A Gaikwad, F P Connolly, G B Mills, J U Gutterma. A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell death and differentiation. vol 14. issue 11. 2008-01-22. PMID:17690712. |
furthermore, avicin d-induced autophagic cell death can be abrogated by knockdown of tuberous sclerosis complex 2 (tsc2), a key mediator linking ampk to mtor inhibition, suggesting that ampk activation is a crucial event targeted by avicin d. these findings indicate the therapeutic potential of avicins by triggering autophagic cell death. |
2008-01-22 |
2023-08-12 |
Not clear |
| Michael J Ravitz, Li Chen, Mary Lynch, Emmett V Schmid. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer research. vol 67. issue 23. 2008-01-22. PMID:18056446. |
among mtor signaling components, myc directly affected transcription of tuberous sclerosis 2 (tsc2), as shown by quantitative mrna analysis and by myc binding to its promoter in chromatin immunoprecipitation assays. |
2008-01-22 |
2023-08-12 |
Not clear |
| Quanri Jin, Lei Feng, Carmen Behrens, B Nebiyou Bekele, Ignacio I Wistuba, Waun-Ki Hong, Ho-Young Le. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer research. vol 67. issue 24. 2008-01-15. PMID:18089792. |
deguelin inhibited survivin expression in tuberous sclerosis complex 2 (tsc2) wild-type mouse embryonic fibroblasts (mef) but not in tsc2-knockout mefs in which mammalian target of rapamycin (mtor) is constitutively active. |
2008-01-15 |
2023-08-12 |
mouse |
| Eleonora Aronica, Karin Boer, Marianna Baybis, Jia Yu, Peter Crin. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta neuropathologica. vol 114. issue 3. 2007-12-26. PMID:17483958. |
we hypothesized that mutations in pten (a cause of hmeg associated with proteus syndrome), tsc1 or tsc2 (tuberous sclerosis complex) genes, which are known to modulate beta-catenin and mtor signaling could cause sporadic hmeg. |
2007-12-26 |
2023-08-12 |
Not clear |
| Chung-Han Lee, Ken Inoki, Magdalena Karbowniczek, Emmanuel Petroulakis, Nahum Sonenberg, Elizabeth Petri Henske, Kun-Liang Gua. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. The EMBO journal. vol 26. issue 23. 2007-12-13. PMID:17962806. |
thus, loss of tsc1 or tsc2, the negative regulators of mtor, results in dramatic accumulation of p53 and apoptosis in response to stress conditions. |
2007-12-13 |
2023-08-12 |
Not clear |
| Asumthia S Jeyapalan, Renan A Orellana, Agus Suryawan, Pamela M J O'Connor, Hanh V Nguyen, Jeffery Escobar, Jason W Frank, Teresa A Davi. Glucose stimulates protein synthesis in skeletal muscle of neonatal pigs through an AMPK- and mTOR-independent process. American journal of physiology. Endocrinology and metabolism. vol 293. issue 2. 2007-09-24. PMID:17551002. |
the response in muscle was associated with increased phosphorylation of protein kinase b (pkb) and enhanced formation of the active eif4e.eif4g complex but no change in phosphorylation of amp-activated protein kinase (ampk), tuberous sclerosis complex 2 (tsc2), mammalian target of rapamycin (mtor), 4e-binding protein-1 (4e-bp1), ribosomal protein s6 kinase (s6k1), or eukaryotic elongation factor 2 (eef2). |
2007-09-24 |
2023-08-12 |
Not clear |
| Li Ma, Julie Teruya-Feldstein, Pauline Bonner, Rosa Bernardi, David Neal Franz, David Witte, Carlos Cordon-Cardo, Pier Paolo Pandolf. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer research. vol 67. issue 15. 2007-09-11. PMID:17671177. |
identification of s664 tsc2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mtor activation in tuberous sclerosis and human cancer. |
2007-09-11 |
2023-08-12 |
human |